Yes GC, crucial point for Neu is not only maximising $$ value for the asset but fast tracking to ph3’s.
Which leads me to think our discussions re our future are well advanced.
Interestingly partnering with big pharma might not be ideal or TO as Neu would not be able to drive this out come.
- Forums
- ASX - By Stock
- NEU
- Ann: P2 trial shows significant improvements in Phelan-McDermid
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-206
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B |
Open | High | Low | Value | Volume |
$19.96 | $19.97 | $19.69 | $4.156M | 209.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 246 | $19.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.99 | 512 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10 | 19.760 |
1 | 1200 | 19.720 |
1 | 540 | 19.710 |
1 | 50 | 19.700 |
1 | 300 | 19.680 |
Price($) | Vol. | No. |
---|---|---|
20.100 | 100 | 1 |
20.190 | 1000 | 1 |
20.410 | 280 | 1 |
20.500 | 2000 | 1 |
20.820 | 2286 | 2 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |